Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research, and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day:
A secondary analysis of CIBMTR data finds functional high-risk phenotype (progression within 12-24 months of front-line induction + ASCT) predicts poor survival in multiple myeloma independent of front-line treatment.”
Title: Functional high-risk phenotype predicts poor survival in multiple myeloma independent of front-line treatment: A secondary analysis of CIBMTR data
Authors: Utkarsh Goel, Catalin Dragomirescu, Saurabh Zanwar, Rafaella Cassano, Kara I. Cicero, Andrew J. Cowan, Rahul Banerjee, Faiz Anwer, Jack Khouri, Danai Dima
You can read the Full Article in British Journal of Haematology.
You can find other articles featuring Robert Orlowski on OncoDaily.
